Two Patent Grants Add to Stem Cell Therapeutics Corp. Patent Portfolio and Expand Geographic Coverage of Key Stem Cell Technologies

by Dr. Allen Davidoff, PhD, CSO ,  Market Watch | 2011-07-28

CALGARY, ALBERTA, Jul 27, 2011 (MARKETWIRE via COMTEX) -- Stem Cell Therapeutics Corp. CA:SSS -5.88% ("SCT" or the "Company") is pleased to announce that it has received notification of the issuance of two additional patents. The first entitled "Use of Luteinizing Hormone (LH) and Chorionic Gonadotropin (hCG) for Proliferation of Neural Stem Cells and Neurogenesis" and was granted by the Australian Patent office; Patent number 2005211847. The second is entitled "Production of Radial Glial Cells" and was issued by the Canadian Intellectual Property Office; Patent number, 2,364,095.

The first patent expands the geographical coverage of SCT's core neurogenesis technology for increasing neural stem cell numbers, or neurogenesis, by using human chorionic gonadotropin (hCG). The technology can be used either directly by administration of a therapeutic dose of drug or in the laboratory to expand the numbers of cells that would later be transplanted into a patient or an animal to induce regeneration of neural tissue in the setting of neurodegenerative disease. This patent is the basis for SCT's NTx(R)-265 therapy.

Related Medical Tourism News
Focus Area